Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Dendreon second-quarter revenue increases to $2.8 million

Dendreon Corporation today reported results for the quarter ended June 30, 2010. Revenue for the quarter ended June 30, 2010 was $2.8 million compared to $25,000 for the quarter ended June 30, 2009. Revenue for the six months ended June 30, 2010 was $2.8 million compared to $55,000 for the six months ended June 30, 2009.

4 Aug 2010

Effects of natural compound against prostate cancer published in Integrative Cancer Therapies

Researchers at Columbia University have published the dramatic effects of a natural 33-ingredient compound against prostate cancer cell lines. The impressive results are found in the most recent publication of Integrative Cancer Therapies.

3 Aug 2010

NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM

Northwest Biotherapeutics, Inc. today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical trials, in which patients with newly diagnosed Glioblastoma multiforme ("GBM"), the most rapid and lethal type of brain cancer, were treated with NWBT's DCVax®-Brain personalized immune therapy.

3 Aug 2010

New surgical technique to maximize preservation of periprostatic anatomy

Stress urinary incontinence is one of the most feared complications of radical prostatectomy. The weighted mean continence rate immediately after catheter removal following robot-assisted laparoscopic radical prostatectomy (RALP) is 25.7%. Evidently, early recovery of urinary continence remains a challenge to be overcome. The Surgery in Motion section of the September issue of European Urology describes the surgical steps of pubovesical complex (PVC)-sparing RALP and presents the preliminary results of the technique.

3 Aug 2010

Study reveals potential marker for prostate cancer

Studies by a Purdue University-led team have revealed a potential marker for prostate cancer that could be the starting point for less invasive testing and improved diagnosis of the disease.

3 Aug 2010

ARO uses Elekta VMAT system for prostate cancer patients

In the expansive region of Australasia—which includes Australia, New Zealand and neighboring islands—Auckland Radiation Oncology Centre is the first to use Elekta VMAT, treating a patient with prostate cancer using a single 100-second arc of radiation. Such rapid treatments change the entire therapy experience for these patients, who have had to remain completely still for seven minutes during radiation delivery for each of 37 to 39 separate treatment sessions or "fractions."

From Elekta 2 Aug 2010

IRIS International closes AlliedPath acquisition

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has closed the acquisition of AlliedPath, Inc., a private, early stage high complexity, CLIA-certified laboratory focused on oncology and molecular diagnostics.

2 Aug 2010

Scientists identify genetic basis for prostate cancer susceptibility in non-European population

A genome-wide study on Japanese subjects has identified 5 new genetic variations associated with prostate cancer and revealed differences and similarities between Europeans and Asians in susceptibility to the disease. Reported in Nature Genetics, the findings offer a first-ever glimpse of the genetic basis for prostate cancer susceptibility in a non-European population.

2 Aug 2010

Cell-of-origin for prostate cancer identified

UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease.

31 Jul 2010

New discovery may lead to effective targeted treatments for prostate cancer: UCLA

30 Jul 2010

Study on link between SNP and concentrations of serum creatinine

Scientists at deCODE genetics and colleagues at Radboud University in the Netherlands today describe how the impact of a single letter variation in the sequence of the human genome conferring risk of kidney disease varies with age and with the onset of other diseases. The study provides independent confirmation of the association made in an earlier study between a version of the the SNP, located on chromosome 16p12, and risk of chronic kidney disease. It also confirmed the link between the SNP and concentrations of serum creatinine, a key indicator of kidney function.

30 Jul 2010

Prostate basal cell can spawn tumors in prostate gland: Research

A type of prostate cell that has been largely ignored by cancer researchers can, in fact, trigger malignant prostate cancer, according to new studies by Howard Hughes Medical Institute (HHMI) scientists and their colleagues.

30 Jul 2010

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Dendreon Corporation announced today the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer. The manuscript is published in the July 29, 2010 issue of the journal.

29 Jul 2010

Scientists develop new surgical procedure for prostate cancer using natural orifices

With a recent first of its kind surgery, physicians at Mayo Clinic in Arizona have developed a new surgical procedure for the treatment of prostate cancer using natural orifices - signaling the next step in the evolution of minimally invasive surgery.

29 Jul 2010

Aggressive prostate cancer patients tend to retain denser bones

Men who develop prostate cancer, especially the more aggressive and dangerous forms that spread throughout the body, tend to retain denser bones as they age than men who stay free of the disease, suggests new research from Johns Hopkins and the National Institute on Aging (NIA), part of the National Institutes of Health.

29 Jul 2010

Aphios awarded US patent for compositions, methods for treating diseases involving 5-α reductase enzyme

Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.

28 Jul 2010

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

NYU Langone opens vascular-targeted photodynamic therapy trial to men with localized prostate cancer

NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer. This novel, minimally invasive procedure uses a light-activated drug to deliver light energy waves by way of laser fibers in order to destroy prostate cancer cells.

28 Jul 2010

National health campaigns make men less likely to choose cancer screening: Study

In Germany, several national health campaigns promote cancer screening by announcing that only one in five German men gets screened. This is supposed to motivate men to have an examination. But a new study published in Psychological Science, a journal of the Association for Psychological Science, finds that this well-meaning message has the exact opposite effect: it makes men less likely to choose to get screened.

28 Jul 2010

Scientists develop laser activated carbon nanoparticles for drug, gene delivery

Using chemical "nanoblasts" that punch tiny holes in the protective membranes of cells, researchers have demonstrated a new technique for getting therapeutic small molecules, proteins and DNA directly into living cells.Carbon nanoparticles activated by bursts of laser light trigger the tiny blasts, which open holes in cell membranes just long enough to admit therapeutic agents contained in the surrounding fluid. By adjusting laser exposure, the researchers administered a small-molecule marker compound to 90 percent of targeted cells - while keeping more than 90 percent of the cells alive.

28 Jul 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Dendreon second-quarter revenue increases to $2.8 million

Effects of natural compound against prostate cancer published in Integrative Cancer Therapies

NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM

New surgical technique to maximize preservation of periprostatic anatomy

Study reveals potential marker for prostate cancer

ARO uses Elekta VMAT system for prostate cancer patients

IRIS International closes AlliedPath acquisition

Scientists identify genetic basis for prostate cancer susceptibility in non-European population

Cell-of-origin for prostate cancer identified

New discovery may lead to effective targeted treatments for prostate cancer: UCLA

Study on link between SNP and concentrations of serum creatinine

Prostate basal cell can spawn tumors in prostate gland: Research

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Scientists develop new surgical procedure for prostate cancer using natural orifices

Aggressive prostate cancer patients tend to retain denser bones

Aphios awarded US patent for compositions, methods for treating diseases involving 5-α reductase enzyme

Regeneron second-quarter total revenues increase to $115.9 million

NYU Langone opens vascular-targeted photodynamic therapy trial to men with localized prostate cancer

National health campaigns make men less likely to choose cancer screening: Study

Scientists develop laser activated carbon nanoparticles for drug, gene delivery

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in